$OPCH

Strategic Execution and Portfolio Recovery Performance beat driven by high-single-digit organic growth in the acute portfolio, where the company's national scale and local responsiveness facilitate time-sensitive hospital discharges. The chronic inflammatory disease (CID) portfolio reached a stabilization point following a first-quarter reset, with patient census beginning to rise sequentially despite biosimilar pricing headwinds.

Ensign Group, Humana, Vitas Healthcare and Option Care Health reported Q2 earnings. Ensign said strong demand, 398 skilled nursing operations, and liquidity of about $262.3M cash plus $591.6M credit capacity, and expects more acquisitions and new states in H2. Humana reaffirmed Medicare Advantage growth and said Gentiva divestiture (~$900M) funds MaxHealth. Vitas reported $443.3M net revenue, up 11.9%. Option Care said results exceeded internal expectations.

Option Care Health (OPCH) reported Q2 CY2026 revenue of $1.44 billion, up 1.9% year over year, beating Wall Street’s expectations. The company guided full-year revenue to about $5.73 billion. Non-GAAP profit was $0.45 per share, 5.4% above consensus. Shares rose about 6.5% to $23.95 after the release.

Option Care Health, Inc. (OPCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026.htm EX-99.1 Document Exhibit 99.1 OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 BANNOCKBURN, IL., July 29, 2026 - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s

Option Care Health (OPCH) is scheduled to report earnings Wednesday morning. Last quarter, it posted revenue of $1.35B, up 1.3% YoY, but missed analysts’ revenue expectations. Full-year revenue guidance missed expectations while EBITDA guidance met. Analysts expect this quarter’s revenue to be flat YoY; the average price target is $28.08 vs $21.65.

Option Care Health shares rose about 3.7% in the morning after Goldman Sachs initiated coverage with a Neutral rating and a $22 price target, implying upside from around $20.51. The stock had fallen 33% over six months. The article notes the company recently reported Q1 2026 revenue of $1.35B (+1.3% YoY) and cut full-year revenue guidance to a $5.73B midpoint.

This article highlights three oversold healthcare stocks – Medtronic (MDT), Option Care Health (OPCH), and Genprex (GNPX) – that could see upward movement in Q2, based on a Relative Strength Index (RSI) near or below 30. It details recent company news, stock performance, and RSI values for each, suggesting an opportunity for investors to consider undervalued companies. The piece utilizes Benzinga Pro data to identify these potential breakouts.

Option Care Health Inc. (OPCH) saw its stock close down significantly after cutting its 2026 revenue outlook due to a larger Stelara reset, despite maintaining its EBITDA/EPS guidance. The article provides comprehensive financial data, analyst ratings history, and recent news headlines related to the company's performance, including insider transactions.

Game Creek Capital LP has acquired a new stake of 55,000 shares in Option Care Health, Inc. (NASDAQ:OPCH) during the third quarter, valued at approximately $1.53 million. Other institutional investors also adjusted their holdings in the company, which now sees 98.05% of its stock owned by hedge funds and institutions. Option Care Health reported earnings per share of $0.46, meeting analyst consensus, and analysts forecast $1.22 EPS for the current year.

Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus rating of "Moderate Buy" from twelve brokerages. Several firms, including Citigroup, Bank of America, Citizens Jmp, and Deutsche Bank, have issued "buy" or "outperform" ratings with target price increases. The company's stock is currently trading around $35.69, with solid financial metrics and substantial institutional ownership.